NIDDK Central Repository - A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.2337/dc11-0981

PubMed ID

21911777

Public Release Type

Journal

Publication Year

2011

Affiliation

ivision of Endocrinology, University of Miami, Miami, Florida, USA. jsosenko@med.miami.edu

Authors

Cuthbertson D, Diabetes Prevention Trial–Type 1 and Type 1 Diabetes TrialNet Study Groups, Eisenbarth G, Krischer JP, Orban T, Palmer JP, Schatz DA, Skyler JS, Sosenko JM, Yu L

Studies

DPT-1

Citation

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Diabetes Prevention Trial–Type 1 and Type 1 Diabetes TrialNet Study Groups. A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care 2011 Nov;34(11):2435-7. Epub 2011 Sep 12.

Abstract

We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D).